ATE538780T1 - Medizinische zusammensetzung, enthaltend ein hmg- coa reduktase inhibitor und ein aminoalkohol derivat, als immunsuppressivum - Google Patents

Medizinische zusammensetzung, enthaltend ein hmg- coa reduktase inhibitor und ein aminoalkohol derivat, als immunsuppressivum

Info

Publication number: ATE538780T1
Authority: AT; Austria
Prior art keywords: hmg; coa reductase; amino alcohol; alcohol derivative; immunosupressant
Prior art date: 2004-07-29

Application number

AT05767088T

Other languages

English (en)

Inventor

Takahide Nishi

Takaichi Shimozato

Takashi Kagari

Hiromi Doi

Original Assignee

Daiichi Sankyo Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-07-29

Filing date

2005-07-28

Publication date

2012-01-15

2005-07-28 Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd

2012-01-15 Application granted granted Critical

2012-01-15 Publication of ATE538780T1 publication Critical patent/ATE538780T1/de

Links

229940121710 HMGCoA reductase inhibitor Drugs 0.000 title abstract 2
150000001414 amino alcohols Chemical class 0.000 title abstract 2
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 title abstract 2
239000001257 hydrogen Substances 0.000 abstract 3
229910052739 hydrogen Inorganic materials 0.000 abstract 3
125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 3
125000000217 alkyl group Chemical group 0.000 abstract 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
125000003545 alkoxy group Chemical group 0.000 abstract 1
125000002947 alkylene group Chemical group 0.000 abstract 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
150000002148 esters Chemical class 0.000 abstract 1
125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 abstract 1
125000005843 halogen group Chemical group 0.000 abstract 1
230000003053 immunization Effects 0.000 abstract 1
238000002649 immunization Methods 0.000 abstract 1
150000002829 nitrogen Chemical class 0.000 abstract 1
229910052760 oxygen Inorganic materials 0.000 abstract 1
239000001301 oxygen Substances 0.000 abstract 1
229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 abstract 1
230000003449 preventive effect Effects 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
125000001424 substituent group Chemical group 0.000 abstract 1
229910052717 sulfur Inorganic materials 0.000 abstract 1
239000011593 sulfur Substances 0.000 abstract 1
229940124597 therapeutic agent Drugs 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Emergency Medicine (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Transplantation (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pyrrole Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT05767088T 2004-07-29 2005-07-28 Medizinische zusammensetzung, enthaltend ein hmg- coa reduktase inhibitor und ein aminoalkohol derivat, als immunsuppressivum ATE538780T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2004222420		2004-07-29
PCT/JP2005/013843 WO2006011554A1 (ja)	2004-07-29	2005-07-28	免疫抑制剤としての医薬組成物

Publications (1)

Publication Number	Publication Date
ATE538780T1 true ATE538780T1 (de)	2012-01-15

Family

ID=35786302

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT05767088T ATE538780T1 (de)	2004-07-29	2005-07-28	Medizinische zusammensetzung, enthaltend ein hmg- coa reduktase inhibitor und ein aminoalkohol derivat, als immunsuppressivum

Country Status (10)

Country	Link
US (1)	US20070149597A1 (de)
EP (1)	EP1782804B1 (de)
KR (1)	KR20070042986A (de)
CN (1)	CN101027048A (de)
AT (1)	ATE538780T1 (de)
BR (1)	BRPI0513888A (de)
CA (1)	CA2575518A1 (de)
ES (1)	ES2377975T3 (de)
TW (1)	TW200611687A (de)
WO (1)	WO2006011554A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BR0306811A (pt) *	2002-01-11	2004-10-26	Sankyo Co	Composto, éster farmacologicamente aceitável do mesmo, composição farmacêutica e métodos para prevenção ou tratamento de doenças autoimunes, da artrite reumatóide e da rejeição causada pelo transplante de vários órgãos em um mamìfero
JP2005272453A (ja)	2004-02-24	2005-10-06	Sankyo Co Ltd	アミノアルコール化合物
CN101014329B (zh)	2004-07-16	2010-09-08	杏林制药株式会社	用于对器官或组织的移植的排异反应或骨髓移植的移植物抗宿主反应预防或治疗的药物组合物
EP1806338B1 (de)	2004-10-12	2016-01-20	Kyorin Pharmaceutical Co., Ltd.	Verfahren zur herstellung von 2-amino-2-[2-[4-(3-benzyloxyphenylthio)-2-chlorphenyl[ethyl]-1,3-propandiolhydrochlorid und hydraten davon, und zwischenprodukte in deren herstellung
TWI418350B (zh) *	2005-06-24	2013-12-11	Sankyo Co	含有ｐｐａｒ調節劑之醫藥組成物的用途
SI1932522T1 (sl) *	2005-10-07	2012-08-31	Kyorin Seiyaku Kk	Terapevtsko sredstvo za jetrno bolezen, ki vsebuje 2-amino-1,3- propandiolni derivat kot aktivno sestavino
KR101346527B1 (ko) *	2005-12-15	2013-12-31	미쓰비시 타나베 파마 코퍼레이션	아민 화합물 및 그 의약 용도
TWI389683B (zh) *	2006-02-06	2013-03-21	Kyorin Seiyaku Kk	A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
JP5188972B2 (ja) *	2006-08-08	2013-04-24	杏林製薬株式会社	アミノリン酸エステル誘導体及びそれらを有効成分とするｓ１ｐ受容体調節剤
MX2009001457A (es) *	2006-08-08	2009-02-19	Kyorin Seiyaku Kk	Derivados de aminoalcohol e inmunosupresores que contienen lo mismo como ingrediente activo.
US20090176744A1 (en) *	2007-11-02	2009-07-09	Concert Pharmaceuticals, Inc.	Deuterated fingolimod
WO2009099174A1 (ja) *	2008-02-07	2009-08-13	Kyorin Pharmaceutical Co., Ltd.	アミノアルコール誘導体を有効成分とする炎症性腸疾患の治療剤又は予防剤
EA019252B1 (ru)	2008-07-23	2014-02-28	Арена Фармасьютикалз, Инк.	ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ (1,2,3,4-ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛ-3-ИЛ)УКСУСНОЙ КИСЛОТЫ, ПРИМЕНИМЫЕ В ЛЕЧЕНИИ АУТОИММУННЫХ И ВОСПАЛИТЕЛЬНЫХ РАССТРОЙСТВ
SI2342205T1 (sl)	2008-08-27	2016-09-30	Arena Pharmaceuticals, Inc.	Substituirani triciklični kislinski derivati kot agonisti S1P1 receptorja, uporabni v zdravljenju avtoimunskih in vnetnih obolenj
SG10201906876PA (en)	2010-01-27	2019-09-27	Arena Pharm Inc	Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
TW201130488A (en) *	2010-02-03	2011-09-16	Daiichi Sankyo Co Ltd	Pyrrole compound
SG183416A1 (en)	2010-03-03	2012-09-27	Arena Pharm Inc	Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof
BE1019432A3 (fr) *	2010-07-23	2012-07-03	Auriga Internat	Utilisation d'isothiocyanates et derives pour le traitement et/ou la prevention des lucites.
MX386419B (es)	2015-01-06	2025-03-18	Arena Pharm Inc	Metodos de condiciones de tratamiento relacionadas con el receptor s1p1.
EP3939965A1 (de)	2015-06-22	2022-01-19	Arena Pharmaceuticals, Inc.	Kristallines l-arginin-salz von (r)-2-(7-(4-cyclopentyl-3-(trifluormethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)essigsäure zur verwendung in s1p1-rezeptor-assoziierten erkrankungen
MA47504A (fr)	2017-02-16	2019-12-25	Arena Pharm Inc	Composés et méthodes de traitement de l'angiocholite biliaire primitive
WO2018151834A1 (en)	2017-02-16	2018-08-23	Arena Pharmaceuticals, Inc.	Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations
ES2987794T3 (es)	2018-06-06	2024-11-18	Arena Pharm Inc	Procedimientos de tratamiento de afecciones relacionadas con el receptor S1P1
CN112955431A (zh)	2018-09-06	2021-06-11	艾尼纳制药公司	可用于治疗自身免疫性病症和炎性病症的化合物
ES3049760T3 (en)	2020-06-08	2025-12-18	Univ Toyama Prefectural	Toll-like receptor 7 activation inhibitors for the treatment of autoimmune diseases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5604229A (en) *	1992-10-21	1997-02-18	Yoshitomi Pharmaceutical Industries, Ltd.	2-amino-1,3-propanediol compound and immunosuppressant
US5948820A (en) *	1994-08-22	1999-09-07	Yoshitomi Pharmaceutical Industries, Ltd.	Benzene compound and pharmaceutical use thereof
DE69524962D1 (de) *	1994-08-22	2002-02-14	Welfide Corp	Benzolderivate und deren medizinische verwendung
ATE298740T1 (de) *	1997-04-04	2005-07-15	Mitsubishi Pharma Corp	2-aminopropan-1,3-diol-verbindungen, ihre medizinische anwendung und zwischenprodukte zu ihrer synthese
WO2002006268A1 (en) *	2000-07-13	2002-01-24	Sankyo Company, Limited	Amino alcohol derivatives
US20030060502A1 (en) *	2001-09-19	2003-03-27	Francois Mach	Treatment of diabetes with statins (HMG-COa reductase inhibitors)
EP1431275B1 (de) *	2001-09-27	2010-04-07	Kyorin Pharmaceutical Co., Ltd.	Diaryletherderivat, dessen additionssalz und immunosuppressivum
MXPA04002679A (es) *	2001-09-27	2004-07-30	Kyorin Seiyaku Kk	Derivados de sulfuro de diarilo, sales de los mismos y agentes inmunosupresores que utilizan los mismos.
BR0306811A (pt) *	2002-01-11	2004-10-26	Sankyo Co	Composto, éster farmacologicamente aceitável do mesmo, composição farmacêutica e métodos para prevenção ou tratamento de doenças autoimunes, da artrite reumatóide e da rejeição causada pelo transplante de vários órgãos em um mamìfero
US7612238B2 (en) *	2002-09-13	2009-11-03	Novartis Ag	Amino-propanol derivatives
JP2005272453A (ja) *	2004-02-24	2005-10-06	Sankyo Co Ltd	アミノアルコール化合物
AU2005237254B2 (en) *	2004-05-03	2010-02-04	Novartis Ag	Combinations comprising a S1P receptor agonist and a JAK3 kinase inhibitor
CN101014329B (zh) *	2004-07-16	2010-09-08	杏林制药株式会社	用于对器官或组织的移植的排异反应或骨髓移植的移植物抗宿主反应预防或治疗的药物组合物
TWI418350B (zh) *	2005-06-24	2013-12-11	Sankyo Co	含有ｐｐａｒ調節劑之醫藥組成物的用途

2005
- 2005-07-27 TW TW094125360A patent/TW200611687A/zh unknown
- 2005-07-28 CN CNA2005800323933A patent/CN101027048A/zh active Pending
- 2005-07-28 BR BRPI0513888-4A patent/BRPI0513888A/pt not_active IP Right Cessation
- 2005-07-28 EP EP05767088A patent/EP1782804B1/de not_active Expired - Lifetime
- 2005-07-28 AT AT05767088T patent/ATE538780T1/de active
- 2005-07-28 KR KR1020077002005A patent/KR20070042986A/ko not_active Withdrawn
- 2005-07-28 WO PCT/JP2005/013843 patent/WO2006011554A1/ja not_active Ceased
- 2005-07-28 ES ES05767088T patent/ES2377975T3/es not_active Expired - Lifetime
- 2005-07-28 CA CA002575518A patent/CA2575518A1/en not_active Abandoned
2007
- 2007-01-26 US US11/698,698 patent/US20070149597A1/en not_active Abandoned

Also Published As

Publication number	Publication date
WO2006011554A1 (ja)	2006-02-02
TW200611687A (en)	2006-04-16
CN101027048A (zh)	2007-08-29
CA2575518A1 (en)	2006-02-02
EP1782804A4 (de)	2010-12-15
KR20070042986A (ko)	2007-04-24
EP1782804B1 (de)	2011-12-28
EP1782804A1 (de)	2007-05-09
US20070149597A1 (en)	2007-06-28
ES2377975T3 (es)	2012-04-03
BRPI0513888A (pt)	2008-05-20

Publication	Publication Date	Title
ATE538780T1 (de)	2012-01-15	Medizinische zusammensetzung, enthaltend ein hmg- coa reduktase inhibitor und ein aminoalkohol derivat, als immunsuppressivum
WO2008146871A1 (ja)	2008-12-04	グルココルチコイド受容体結合活性を有する、スルホン酸エステル又はスルホン酸アミド構造を導入したフェニル基を置換基として有する新規１，２，３，４－テトラヒドロキノキサリン誘導体
EP1780209A4 (de)	2009-06-03	Oximesterverbindung und photopolymerisationsinitiator, der eine solche verbindung enthält
ATE556058T1 (de)	2012-05-15	1-(2h)-isochinolonderivat
ATE488490T1 (de)	2010-12-15	Tripentylcitrate und deren verwendung als weichmacher
DK1265606T3 (da)	2007-02-12	Celleadhæsionsinhibitorer
WO2005105732A8 (en)	2007-04-19	Substituted methyl aryl or heteroaryl amide compounds
DE60043349D1 (de)	2009-12-31	Chinazolin-derivate und ihre verwendung als arzneimittel
EA200870358A1 (ru)	2009-02-27	2-(циклический амино) пиримидоновые производные в качестве ингибиторов tpk1
GB2457416A (en)	2009-08-19	Directly photodefinable polymer compositions and methods thereof
HRP20070430T3 (en)	2007-11-30	(3-oxo-3,4-dihydro-quinoxalin-2-yl-amino)-benzamide derivatives and related compounds as glycogen phosphorylase inhibitors for the treatment of diabetes and obesity
EP1642880A4 (de)	2006-11-15	Proteininhibitoren der hsp90-familie
PY08034070A (es)	2014-02-03	Derivados de 1, 2, 4, 5-tetrahidro -3-H- benzazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen.
WO2007099162A3 (fr)	2007-11-29	Derive de resveratrol a longue chaine hydroxylee utiles comme neurotrophiques
DK1008592T3 (da)	2006-06-06	Cykliske amidderivater, som inhiberer cathepsin K
MX2009012380A (es)	2009-12-03	Compuestos de heteroarilamida pirimidona.
TW200724136A (en)	2007-07-01	Pharmaceutical compositions comprising PPAR modulator
NO20064297L (no)	2006-11-23	Aminoalkoholforbindelse
ATE374773T1 (de)	2007-10-15	Polycyclische verbindungen als potenten alpha2- adrenoceptor antagonisten
EP1634874A4 (de)	2008-04-02	Imidazolidinderivate
ATE259376T1 (de)	2004-02-15	Heterozyklische verbindungen, ihre zwischenprodukte und elastase-inhibitoren
AR046310A1 (es)	2005-11-30	Compuestos nucleosidicos para el tratamiento de enfermedades virales. composiciones farmaceuticas.
TW200745104A (en)	2007-12-16	Multikinase inhibitor
CA2373395A1 (en)	2002-08-28	Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors
NO20054053L (no)	2005-10-31	Triazolforbindelser anvendbare i terapi.